Phase III Study Comparing Efficacy and Safety of AFOLIA vs Gonal-f® RFF in Women (35 to 42) Undergoing IVF
Status:
Completed
Trial end date:
2016-11-14
Target enrollment:
Participant gender:
Summary
The purpose of this study is to show that AFOLIA, a recombinant manufactured human follicle
stimulating hormone (r-hFSH) has a similar efficacy and safety profile compared to Gonal-f®
RFF.